MMAD

Cat. No.:	HY-15581
CAS No.:	203849-91-6
Molecular Formula:	C ₄₁ H ₆₆ N ₆ O ₆ S
Molecular Weight:	771.06
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	4°C, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.

SOLVENT & SOLUBILITY

®

MedChemExpress

		Solvent	1 mg	5 mg	10 mg
	Preparing Stock Solutions	Concentration			
		1 mM	1.2969 mL	6.4846 mL	12.9692 mL
		5 mM	0.2594 mL	1.2969 mL	2.5938 mL
		10 mM	0.1297 mL	0.6485 mL	1.2969 mL

BIOLOGICAL ACTIVITY		
Description	MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).	
IC_{50} & Target	Auristatin	
In Vitro	MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

Product Data Sheet

REFERENCES

[1]. Chudasama V, et al. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016 Feb;8(2):114-9.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA